Selected for UTokyo IPC 1st Round, an incubation program run by The University of Tokyo Edge Capital Partners
iMed Technologies, Inc. (headquartered in Shibuya-ku, Tokyo; Representative Director and CEO, Kenichi Kono; Representative Director and COO, Motohisa Kaneko; hereafter iMed Technologies), which develops surgical support AI for ischemic stroke and subarachnoid hemorrhage, has been selected for UTokyo IPC 1st Round, an incubation program run by The University of Tokyo Edge Capital Partners (hereafter UTokyo IPC).
iMed Technologies, Inc. (headquartered in Shibuya-ku, Tokyo; Representative Director and CEO, Kenichi Kono; Representative Director and COO, Motohisa Kaneko; hereafter iMed Technologies), which develops surgical support AI for ischemic stroke and subarachnoid hemorrhage, has been selected for UTokyo IPC 1st Round, an incubation program run by The University of Tokyo Edge Capital Partners, Inc. (hereafter UTokyo IPC).
*For details, see the following website. https://www.utokyo-ipc.co.jp/2019/10/utokyoipc-1stround_1st_final/
With the support of UTokyo IPC 1st Round, iMed Technologies will accelerate the commercialization of its surgical support AI for ischemic stroke and subarachnoid hemorrhage.
■About iMed Technologies, Inc. Under the mission of “Delivering safe surgery to the world,” iMed Technologies develops surgical support AI for ischemic stroke and subarachnoid hemorrhage.
■iMed Technologies, Inc. Company Profile Company name: iMed Technologies, Inc. Address: 5F Eclat Shibuya, 3-6-2 Shibuya, Shibuya-ku, Tokyo Founded: April 1, 2019 Business: Development of surgical support AI for ischemic stroke and subarachnoid hemorrhage Representatives: Representative Director and CEO, physician Kenichi Kono Representative Director and COO, Motohisa Kaneko